Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities
Neuro-Oncology · 05.07.2024 · 26 (7) · 1335-1351
DOI: 10.1093/neuonc/noae038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 02.03.2024. Verfasst von Bo Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Neoplasms, Germ Cell and Embryonal, Brain Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Intracranial germ cell tumors (IGCTs) are a rare group of malignancies that are clinically classified as germinomas and nongerminomatous germ cell tumors (NGGCTs). Previous studies have found that somatic mutations involving the mitogen-activated protein kinase/mTOR signaling pathway are common early events. However, a comprehensive genomic understanding of IGCTs is still lacking.
Methods
We established a cohort including over 100 IGCTs and conducted genomic and transcriptomic sequencing.
Results
We identified novel recurrent driver genomic aberrations, including USP28 truncation mutations and high-level copy number amplification of KRAS and CRKL caused by replication of extrachromosomal DNA. Three distinct subtypes associated with unique genomic and clinical profiles were identified with transcriptome analysis: Immune-hot, MYC/E2F, and SHH. Both immune-hot and MYC/E2F were predominantly identified in germinomas and shared similar mutations involving the RAS/MAPK signaling pathway. However, the immune-hot group showed an older disease onset age and a significant immune response. MYC/E2F was characterized by a younger disease onset age and increased genomic instability, with a higher proportion of tumors showing whole-genome doubling. Additionally, the SHH subtype was mostly identified in NGGCTs.
Conclusions
Novel genomic aberrations and molecular subtypes were identified in IGCTs. These findings provide molecular basis for the potential introduction of new treatment strategies in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
- Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Key Laboratory of Pediatric Hematology & Oncology Ministry of Health, Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Bo Li, Xiaoguang Qiu
Zitieren
APA
Li, B., Zhao, S., Li, S., Li, C., Liu, W., Li, L., Cui, B., Liu, X., Chen, H., Zhang, J., Ren, Y., Liu, F., Yang, M., Jiang, T., Liu, Y., & Qiu, X. (2024). Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities. Neuro-Oncology, 26(7), 1335-1351. https://doi.org/10.1093/neuonc/noae038
Vancouver
Li B, Zhao S, Li S, Li C, Liu W, Li L, et al. Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities. Neuro-Oncology. 2024;26(7):1335-1351. doi:10.1093/neuonc/noae038
BibTeX
@article{Li2024,
author = {Li, Bo and Zhao, Shuang and Li, Shouwei and Li, Chunde and Liu, Wei and Li, Lin and Cui, Bowen and Liu, Xing and Chen, Huiyuan and Zhang, Jing and Ren, Yin and Liu, Fei and Yang, Ming and Jiang, Tao and Liu, Yu and Qiu, Xiaoguang},
title = {Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {7},
pages = {1335--1351},
doi = {10.1093/neuonc/noae038}
}
EUVIMED